Novo Nordisk Stock: Q3 Miss, Oversold Charts, and Lobbying Questions
Novo Nordisk shares fell sharply after the Danish pharmaceutical giant reported weaker-than-expected third-quarter results, missing Wall Street estimates on both revenue and earnings per share.
- Novo Nordisk shares fall after Q3 results miss market expectations.
- Political trades and lobbying disclosures draw new attention to the company.
- Technical indicators show strong bearish sentiment with oversold conditions.
- Strategic acquisitions and new obesity drug trials aim to support future growth.
The company’s financial update comes as new data and political disclosures raise questions about market sentiment surrounding one of Europe’s largest healthcare firms.
The stock, trading under the ticker NVO, dropped near $47 in early Wednesday trading, reflecting growing investor caution. Technical indicators show a strong sell signal on daily charts, with moving averages pointing decisively lower.
Q3 Results Fall Short of Expectations
Novo Nordisk’s third-quarter earnings per share came in at $0.69, below the expected $0.76 — a miss of roughly 9%. Revenue totaled $11.52 billion, down 3% from analyst forecasts. Despite that, the company’s quarterly revenue rose year-over-year to DKK 74.98 billion (about $10.6 billion), supported by steady growth in obesity and diabetes treatments.
$NVO (Novo Nordisk) #earnings are out: pic.twitter.com/05qDZw2DXO
— The Earnings Correspondent (@earnings_guy) November 5, 2025
Compared to the same quarter last year, Novo Nordisk’s earnings per share declined 22%, while revenue improved 12%. However, both figures fell sequentially, with EPS down 25% and revenue 3% lower quarter-over-quarter. Analysts say the drop signals cooling demand and supply bottlenecks for GLP-1-based drugs, prompting a downward revision of sales guidance.
Strategic Moves Amid Market Volatility
In a bid to strengthen its treatment portfolio, Novo Nordisk has agreed to acquire Akero Therapeutics Inc., adding a late-stage liver disease candidate to its research pipeline. The company also launched a phase 3 program for cagrilintide, aimed at enhancing its obesity management offerings. These moves are part of a broader strategy to sustain growth and maintain leadership in the fast-evolving metabolic disorder segment.
Novo Nordisk’s profitability remains strong, with an operating margin near 46% and a net margin above 35%. Its balance sheet shows prudent leverage with a debt-to-equity ratio of 0.59, and an Altman Z-score of 4.72 reflects solid financial health.
Lobbying Links and Political Trades Stir Controversy
Recent disclosures have added a new twist to the story. According to data from Quiver Quantitative, several U.S. politicians — including Marjorie Taylor Greene and Lisa McClain — reported purchases of Novo Nordisk shares in the weeks leading up to the company’s earnings release. At the same time, filings revealed that Novo Nordisk spent over $1.7 million lobbying the U.S. government in late October, fueling speculation about the timing and motives behind these moves.
Politicians have been loading up on $NVO & Novo Nordisk has been lobbying millions to the U.S. government…
Somethings cooking pic.twitter.com/8guvNT1IRh
— Bilaal- BD investing (@bdinvestingg) November 5, 2025
Market commentators have described the overlap as “curious,” though there is no evidence of wrongdoing. Still, the combination of insider trades, lobbying activity, and disappointing earnings has amplified investor unease.
Technical and Market Sentiment
TradingView data confirms the growing bearish tone. On the daily chart, Novo Nordisk’s Class B stock trades near DKK 311.60 after slipping 1.14% in the latest session. The RSI has fallen to 30.6, nearing oversold levels, while the MACD remains in negative territory, signaling continued downward momentum. Analysts note that while the stock could see a short-term technical rebound, the broader trend remains weak until momentum indicators turn positive again.
According to TradingView’s one-day technical summary, Novo Nordisk’s stock is flashing a clear Sell signal, with 14 indicators on sell versus only 2 on buy. Moving averages register a Strong Sell, confirming the bearish tone. The relative strength index (RSI) at 23.6 also indicates the stock is oversold, which could precede a short-term rebound — but analysts remain cautious.
With a market capitalization exceeding DKK 214 billion and a P/E ratio of just over 13, Novo Nordisk remains a healthcare powerhouse. Yet, investors appear divided on whether the current weakness represents a buying opportunity or the beginning of a longer correction.
Outlook
Despite the short-term pressure, Novo Nordisk’s long-term outlook remains anchored in its strong pipeline, robust financials, and ongoing expansion into new therapeutic areas. However, with political scrutiny intensifying and technical indicators flashing red, the next few weeks could be pivotal in determining whether NVO stabilizes or extends its decline.
The information provided in this article is for educational purposes only and does not constitute financial, investment, or trading advice. Coindoo.com does not endorse or recommend any specific investment strategy or cryptocurrency. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.
Alexander Zdravkov is a person who always looks for the logic behind things. He has more than 3 years of experience in the crypto space, where he skillfully identifies new trends in the world of digital currencies. Whether providing in-depth analysis or daily reports on all topics, his deep understanding and enthusiasm for what he does make him a valuable member of the team.
